WARNING LETTER
Erkul Kozmetik Sanayi ve Ticaret A.S.
MARCS-CMS 721964 —
June 02, 2026
Delivery Method:
VIA UPS
Reference #:
320-26-85
Product:
Drugs
Recipient:
Recipient Name
Ms. Fatma Faize Aktar
Recipient Title
General Manager
Erkul Kozmetik Sanayi ve Ticaret A.S.
Cihangir Mahallesi, Petrol Ofisi Caddesi No: 1
Avcilar
/
İstanbul
Turkey
Issuing Office:
Center for Drug Evaluation and Research (CDER)
United States
Warning Letter
320-26-85
June 2, 2026
Dear Ms. Aktar:
Your facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 25, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Erkul Kozmetik Sanayi ve Ticaret A.S., FEI 3012641739, at Cihangir Mahallesi, Petrol Ofisi Caddesi No: 1, Avcilar, Istanbul, as well as subsequent correspondence.
This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).
Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).
Following review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:
1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).
Your firm manufactures OTC
(b)(4)
drug products labeled to contain the active drug ingredient
(b)(4)
. These drug products are labeled and formulated to contain the inactive ingredient talc. For example,
(b)(4)
is composed of more than
(b)(4)
%
talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.
1,2
Your
(b)(4)
drug products containing talc are considered higher-risk drugs as they pertain to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation.
You have not demonstrated that you have appropriately tested incoming talc-containing drug components used in the manufacture of your
(b)(4)
drug products for identity, purity, strength, and quality. In response to our 704(a)(4) request, you indicate that you did not conduct identity testing on the talc you used to manufacture drug products. Furthermore, your records indicate that neither you nor your suppliers conducted appropriate tests for asbestos in talc.
In subsequent correspondence you provided documentation that you had a contract laboratory test components for the presence of asbestos, for which they reported “Not Detected” results, but you have not demonstrated that this testing was conducted on all lots used in drug product manufacturing. Additionally, you have not demonstrated that your test methods are validated to show that they are suitable for their intended use. Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.
As a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.
In response to this letter, provide:
Identity, assay and impurity test results from testing retains for all lots of talc-containing drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.
A description of how you will test each component lot for conformity with all appropriate written specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.
A full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.
The chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.
2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).
Your quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that your test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). The current United States Pharmacopeia (USP) talc monograph could be used to meet this requirement for talc; however, specifications for your components containing talc failed to include testing for assay and multiple impurities (e.g., limits of
(b)(4)
), as well as total combined molds and yeasts enumeration. Notably, you failed to have a specification that includes a test for the absence of asbestos. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.
Your QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document
Quality Systems Approach to Pharmaceutical CGMP Regulations
for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https://www.fda.gov/media/71023/download.
In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:
A determination of whether procedures used by your firm are robust and appropriate.
Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.
A complete and final review of representative batches within expiry and their related information before the QU disposition decision.
Deregistration and Ceasing of Distribution of Drugs to the U.S.
Shortly after receiving our records request, you cancelled your drug registration, and sent correspondence indicating that you had not shipped drug products to the United States after December 2024. Contrary to this statement, FDA import records indicate that your
(b)(4)
drug products had been shipped to the United States in 2025. FDA placed your firm on import alert on March 17, 2026, and your firm may remain on import alert until FDA can inspect your facility and verify you are in compliance with CGMP.
Quality Specifications Regarding Talc
Talc is a USP article, whose specification can be found in the current USP talc monograph. As mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that drugs including components, such as talc, that are recognized in the USP are generally required to meet the current applicable USP monograph under section 501(b) of the FD&C Act. FDA reviewed your specifications for talc-containing components and they are incomplete when compared to the current USP specification. We note that the USP has recently revised its monograph for talc which includes updated technical requirements for asbestos testing in talc and is currently scheduled to be official in June 2026.
Conclusion
The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.
FDA placed all drugs offered for import into the United States from your firm on Import Alert 66-40 on March 17, 2026.
Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.
Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Erkul Kozmetik Sanayi ve Ticaret A.S., Cihangir Mahallesi, Petrol Ofisi Caddesi No: 1, Avcilar, Istanbul into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).
This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.
Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012641739 and ATTN: Sena G. Dissmeyer.
Sincerely,
/S/
Francis Godwin
Director
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research
CC:
(b)(4)
_______________________
1
https://www.cancer.gov/about-cancer/causes-prevention/risk/substances/asbestos
2
https://www.atsdr.cdc.gov/asbestos/health-effects/
Content current as of:
06/09/2026
Regulated Product(s)
Drugs